anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Left ventricular (LV) unloading by Impella, an intravascular microaxial pump, has been shown to exert dramatic cardioprotective effects in acute clinical settings of cardiovascular diseases. Total Impella support (no native LV ejection) is far more efficient in reducing LV energetic demand than partial Impella support, but the manual control of pump speed to maintain stable LV unloading is difficult and impractical. We aimed to develop an Automatic IMpella Optimal Unloading System (AIMOUS), which controls Impella pump speed to maintain LV unloading degree using closed-feedback control. We validated the AIMOUS performance in an animal model.
METHODS: In dogs, we identified the transfer function from pump speed to LV systolic pressure (LVSP) under total support conditions (n = 5). Using the transfer function, we designed the feedback controller of AIMOUS to keep LVSP at 40 mmHg and examined its performance by volume perturbations (n = 9). Lastly, AIMOUS was applied in the acute phase of ischemia-reperfusion in dogs. Four weeks after ischemia-reperfusion, we assessed LV function and infarct size (n = 10).
RESULTS: AIMOUS maintained constant LVSP, thereby ensuring a stable LV unloading condition regardless of volume withdrawal or infusion (±8 ml/kg from baseline). AIMOUS in the acute phase of ischemia-reperfusion markedly improved LV function and reduced infarct size (No Impella support: 13.9 ± 1.3 vs. AIMOUS: 5.7 ± 1.9%, P < 0.05).
CONCLUSIONS: AIMOUS is capable of maintaining optimal LV unloading during periods of unstable hemodynamics. Automated control of Impella pump speed in the acute phase of ischemia-reperfusion significantly reduced infarct size and prevented subsequent worsening of LV function.
Patients receive fludarabine IV and cyclophosphamide IV on days -5 to -3. Patients receive TAG72-CAR T cells IP on day 0.
Dose escalation to determine the maximum tolerated dose (MTD) of CPX-351 in combination with Gemtuzumab Ozogamicin in participants with newly diagnosed acute myeloid leukemia. Participants will be treated in cohorts of size three to six and the dosage will be escalated if the clinical toxicity is acceptable. A total of 3 dose levels will be used.
Disruption of fluid balance is common in critical illness. Many critical illnesses are inflammatory in nature and associated with capillary leak and swelling of tissues. While fluid administration may be necessary for the immediate resuscitation of a patient in shock, in the long term it may worsen survival and lead to complications. This is especially true in acute respiratory failure, where excess fluid can lead to a longer duration of mechanical ventilation, longer time in the ICU, and a greater need for dialysis. There is also evidence that conservative fluid administration can prevent complications. Fluid overload is associated with increased healthcare resource utilization and cost.

Much of the fluid administered to patients while in the adult ICU in the United States is administered as medications via large volume infusion pumps. This is a descriptive study to gather data on fluid balance, intravenous medication administration, electrolyte balance, and diuretic and dialysis use in patients with acute respiratory failure who might benefit from a strategy designed to limit fluid administration. The information will be used to design an interventional trial of small volume medication infusion.
BACKGROUND: Although obesity may be associated with an increased risk of perioperative and postoperative complications after total knee arthroplasty (TKA), body mass index (BMI) cutoffs for TKA patient selection remain a controversial topic. This study aimed to investigate patient-reported outcomes, satisfaction, and pain among BMI classes at 3 months and 1 year following TKA.
METHODS: A total of 2,365 patients were categorized into Centers for Disease Control BMI classes according to preoperative values. The BMI distribution over the cohort demonstrated 7 underweight, 340 healthy weight, 731 overweight, 666 Class I, 391 Class II, and 230 Class III obesity. Preoperative and postoperative Knee injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS JR), satisfaction, and pain scores were compared by BMI class by Analysis of Variance with pairwise comparisons.
RESULTS: Preoperative KOOS JR scores and satisfaction scores were both significantly greater for healthy weight patients compared to Class III patients (P < .0001). However, KOOS JR, satisfaction, and pain did not vary by BMI class postoperatively. Changes in scores from baseline suggest larger improvements with increasing BMI class, where Class III patients reported the greatest improvements in KOOS JR (23.24 ± 15.67, P < .0001) and pain scores (-3.56 ± 2.65, P < .0001) at 90 days. Significantly greater improvement with increasing BMI was also present at 1-year postoperatively for KOOS JR scores. A total of 85.8% of Class III patients reached the Minimal Clinically Important Difference for KOOS JR at 90 days compared to 76.8% of the healthy weight group (P = .03). Differences between BMI groups in the proportion reaching Minimal Clinically Important Difference at 1 year were not significant.
CONCLUSIONS: Patients of higher BMI reported greater and earlier improvements in satisfaction, knee function, and pain following TKA. Shared decision-making remains paramount to preoperative surgical evaluation. However, rationing of this surgical intervention based on BMI alone may not be warranted.
A randomized, double-blinded study will be conducted to validate the results of previous literature on the use of budesonide in the prevention of altitude sickness. It will be conducted using healthy participants overseen by experienced wilderness medicine and altitude researchers from the Altitude Research Center at University of Colorado Denver. Participants will be recruited from the Denver community and prescreened for eligibility via phone. 100 participants, after consenting, will have baseline data and blood collected and will begin budesonide therapy 72 hours prior to being taken from Denver to Pikes Peak, where they will be observed at altitude for 18 hours. Patients will have the opportunity to withdraw consent at any time and will be monitored continuously by physician-researchers. Data collection and blood draws will be performed at specific time points and analyzed for efficacy of budesonide vs. placebo in the incidence of altitude sickness.
FIELD: medicine. SUBSTANCE: method involves the use of the bioregulating agent epytalamine in addition to the course of the conventional complex intense therapy. Epytalamine is administrated at severe craniocerebral trauma by endolumbar route at the dose 20 mg dissolved in 1.5-5 ml of 10% glucose solution for 3 days. Then the preparation is administrated intravenously at the dose 20 mg in every 24 h for 7 days. Method provides the recovery of damaged neuroregulation of immunogenesis in the brain after trauma by modulation of the functional activity of hypothalamus-hypophysis system. Method can be used in neurotraumatology and neuroreanimatology in the complex treatment of patients with the brain traumatic disease. EFFECT: improved method of treatment, enhanced effectiveness of treatment. 2 ex
NOVEL METHOD TO TREAT BLOOD            ABSTRACT OF THE DISCLOSURE       It is well known that the transfusion of human blood and blood components carries with it a substantial risk of transmission of AIDS and many other diseases.  This disclosure describes a method of disinfecting red blood cells to make them safer for human transfusion, while maintaining their biologic activity.  A sterilizing solution is prepared from, e.g., a commercially available disinfectant (LDtm Alcide Corporation) containing primarily lactic acid and sodium chlorite.  Normal saline solution is used as diluent instead of distilled water.         The red cells are exposed to the disinfectant for a time sufficient to inactivate or reduce the infectivity of disease agents.  The normal-saline environment prevents or deters hemolysis.  The blood cells are then washed with normal saline solution until the disinfectant concentration is insignificant.  The blood is then safe for human transfusion.
Impaired Liver Function

Do not use Microgestin 24 Fe in women with liver disease, such as acute viral hepatitis or severe (decompensated) cirrhosis of liver [see Contraindications (4)].Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded. Discontinue Microgestin 24 Fe if jaundice develops.

Liver Tumors

Microgestin 24 Fe is contraindicated in women with benign and malignant liver tumors [see Contraindications (4)]. Hepatic adenomas are associated with COC use. An estimate of the attributable risk is 3.3 cases per 100,000 COC users. Rupture of hepatic adenomas may cause death through intra-abdominal hemorrhage.

Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (>8 years) COC users. However, the risk of liver cancers in COC users is less than one case per million users.
Remifentanil HCl is a Schedule II controlled drug substance that can produce drug dependence of the morphine type and has the potential for being abused.

Remifentanil HCl contains remifentanil, a substance with a high potential for abuse similar to other opioids including fentanyl, alfentanil, sufentanil, and meperidine. Remifentanil HCl can be abused and is subject to misuse, addiction, and criminal diversion.

Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that develop after repeated substance use and includes: a strong desire to take the drug, difficulties in controlling its use, persisting in its use despite harmful consequences, a higher priority given to drug use than to other activities and obligations, increased tolerance, and sometimes a physical withdrawal. Abuse and addiction are separate and distinct from physical dependence and tolerance. Health care providers should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical dependence in all addicts. In addition, abuse of opioids can occur in the absence of true addiction.

Remifentanil HCl, like other opioids, can be diverted for non-medical use into illicit channels of distribution. Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests, as required by state and federal law, is strongly advised.

Risks Specific to Abuse of Remifentanil HCl

Abuse of remifentanil HCl poses a risk of overdose and death. The risk is increased with concurrent use of remifentanil HCl with alcohol and other central nervous system depressants.

Parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and HIV.
Exposure of colorectal cancer (CRC) cells to ionizing radiation results in a growth arrest, with cells blocked in both the G1 and G2 phases of the cell cycle. The G1 block has been shown to be due to the p53-mediated induction of the cyclin-dependent kinase inhibitor p21<WAF1/CIP1/SDI1>, but the basis for the G2 arrest is unknown. Through a quantitative analysis of gene expression patterns in CRC cell lines, we have discovered that 14-3-3sigma is strongly induced by gamma-irradiation and other DNA-damaging agents. The induction of 14-3-3sigma is mediated by a p53-responsive element located 1.815 kb upstream of its transcription start site. Exogenous introduction of 14-3-3sigma into cycling cells results in a G2 block similar to that observed following irradiation. These results document a molecular mechanism for G2/M control that is regulated in human cells by p53.
Disclosed is a method for controlling fish parasites, which comprises continuously administering a folic acid synthesis inhibitor and/or a folic acid activation inhibitor to a fish at a dose of 1 to 50 mg/kg fish body weight per day for one to two weeks. Preferably, a combination of a folic acid synthesis inhibitor and a folic acid activation inhibitor is used. As the folic acid synthesis inhibitor, a sulfa drug is preferred. As the folic acid activation inhibitor, a dihydrofolate reductase inhibitor, a folic acid antagonist, or the like can be used. The parasite control agent can control fish parasites through oral administration. The parasite control agent is particularly effective on ciliate fish parasites.
This group will include 40 healthy volunteers. Two sessions of moxibustion intervention will be performed in the Heart meridian and Lung meridian successively. The washout period between the two sessions is at least one day.
Electro-muscular stimulation using NeuroTrac MyoPlus 2/4. All participants taking part will be allocated to the Electronic Muscle Stimulation Activity (EMS) intervention from baseline for the duration of 12 weeks. There will be 6 EMS sessions of 35mins/per session each week.
The invention relates to a roxithromycin monohydrate crystal, a preparation method thereof and a compound dry suspension containing the roxithromycin monohydrate crystal and an ambroxol hydrochloride composition. The roxithromycin monohydrate crystal provided by the invention has a molecular formula of C41H76N2O15.H2O. The preparation method comprises the steps of sample dissolving, devitrifying, smashing, water exchanging and drying. The invention also provides a composition containing the crystal, and the composition comprises 30-70 parts by weight of roxithromycin monohydrate crystals, 5-15 parts by weight of ambroxol hydrochloride, 10-30 parts by weight of xanthan gum, 10-50 parts by weight of hydroxypropyl methylcellulose, 2870-2920 parts by weight of cane sugar and a proper amount of banana essence. The crystal provided by the invention has low moisture absorption and good stability. The composition provided by the invention contains the roxithromycin monohydrate crystal, the suspension is in a good condition, the dissolution rate of medicaments is increased, and the bioavailability is improved.
The invention discloses a traditional Chinese medicine foot-bathing health-maintaining health-care prescription for treating calcaneal-shoulder syndrome. Calcaneal-shoulder syndrome is a clinical common frequently-occurring disease, is mostly found in middle aged and elderly people, and easily affects obese people. The prescription includes calcaneal fat pad lesion, aponeurositis plantaris, calcaneal periostitis, calcaneal spur and the like. The prescription is prepared from nine traditional Chinese medicinal materials: 25-35g of lycopodium clavatum, 25-35g of caulis spatholobi, 25-35g of pyrola rotundifolia, 5-7g of frankincense, 8-12g of safflower, 15-20g of myrrh, 15-20g of rheum officinale, 15-20g of radix clematidis, 15-20g of ligusticum wallichii and the like. The method for preparing and applying the prescription comprises the following steps: firstly, putting the nine traditional Chinese medicinal materials into a marmite, and decocting for half an hour; removing residues to obtain decoction, pouring into a non-metallic foot-bathing basin, and adding 3-5kg of hot water at 38-40 DEG C in a ratio of hot water to cold water being 2:1; soaking feet when ankle joints are overflowed, wherein soaking is performed twice a day, in the morning and evening, for 1 hour each time. Each dose of the prescription can be used for soaking for 3 days. The prescription has the effects of promoting blood circulation to relieve pain, removing blood stasis and dredging collaterals, and is used for treating calcaneal pains.
All consecutive stroke patients from five time points, i.e. 2004, 2006, 2008, 2010, 2012, 2014, 2016, 2018 are selected for analysis.
BACKGROUND: Primary graft dysfunction (PGD) is the leading cause of early morbidity and mortality after lung transplantation. Accurate prediction of PGD risk could inform donor approaches and perioperative care planning. We sought to develop a clinically useful, generalizable PGD prediction model to aid in transplant decision-making.
METHODS: We derived a predictive model in a prospective cohort study of subjects from 2012 to 2018, followed by a single-center external validation. We used regularized (lasso) logistic regression to evaluate the predictive ability of clinically available PGD predictors and developed a user interface for clinical application. Using decision curve analysis, we quantified the net benefit of the model across a range of PGD risk thresholds and assessed model calibration and discrimination.
RESULTS: The PGD predictive model included distance from donor hospital to recipient transplant center, recipient age, predicted total lung capacity, lung allocation score (LAS), body mass index, pulmonary artery mean pressure, sex, and indication for transplant; donor age, sex, mechanism of death, and donor smoking status; and interaction terms for LAS and donor distance. The interface allows for real-time assessment of PGD risk for any donor/recipient combination. The model offers decision-making net benefit in the PGD risk range of 10% to 75% in the derivation centers and 2% to 10% in the validation cohort, a range incorporating the incidence in that cohort.
CONCLUSION: We developed a clinically useful PGD predictive algorithm across a range of PGD risk thresholds to support transplant decision-making, posttransplant care, and enrich samples for PGD treatment trials.
Postpartum depression and anxiety are the two most common perinatal mental health disorders (mental health disorders occurring during pregnancy and the year after birth), with prevalence rates higher among women living in Qatar than in most western countries. The negative outcomes associated with postpartum depression and anxiety are profound, and include poor birth outcomes, poor parenting practices, and compromised infant and young child development. Although interventions exist to prevent postpartum depression and anxiety, to date there have been no studies that have attempted to prevent postpartum depression or anxiety among Arabic speaking women in the Middle East, including Qatar. This project brings together a multidisciplinary team of researchers and clinicians from Sidra Medicine (Qatar) and Northwestern University Feinberg School of Medicine (USA) to conduct a first-of-its-kind study that examines the feasibility, acceptability, and outcomes associated with an evidence-based postpartum depression intervention-Mothers and Babies (MB). MB has been widely used in the USA and has been linguistically translated into Arabic and successfully delivered to Arab-American women. In Phase One of this project, the investigators will culturally and contextually adapt Mothers and Babies to ensure its suitability for use with women residing in Qatar. In Phase Two, the investigators will conduct a small pilot study that examines the acceptability, appropriateness, and feasibility of the adapted Mothers and Babies intervention. Specifically, the investigators will deliver the adapted intervention to 10 women receiving prenatal care at Sidra Medicine. In Phase Three, the investigators will conduct a randomized controlled trial (n = 210) to determine the effectiveness of the adapted Mothers and Babies intervention on depressive symptoms, anxiety symptoms, and perceived stress among women receiving prenatal care at Sidra Medicine. As part of the randomized controlled trial, the investigators will recruit a sub-group of 40 women with diabetes, given the high prevalence of diabetes among women in Qatar and the negative outcomes associated with diabetes on mother and child. The investigators will explore whether the cognitive-behavioral techniques in Mothers and Babies are effective not only in promoting better mental health outcomes among this subgroup, but also better diabetes self-management.
The mobile app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parents are asked to play with their child for 15 minutes 3-4 times per week for 8 weeks.
### Digoxin

Studies in healthy volunteers have shown that dofetilide does not affect the pharmacokinetics of digoxin. In patients, the concomitant administration of digoxin with dofetilide was associated with a higher occurrence of Torsade de Pointes. It is not clear whether this represents an interaction with dofetilide or the presence of more severe structural heart disease in patients on digoxin; structural heart disease is a known risk factor for arrhythmia. No increase in mortality was observed in patients taking digoxin as concomitant medication.

### Other Drugs

In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides), and theophylline did not affect the pharmacokinetics of dofetilide. In addition, studies in healthy volunteers have shown that dofetilide does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of propranolol (40 mg twice daily), phenytoin, theophylline, or oral contraceptives.

Population pharmacokinetic analyses were conducted on plasma concentration data from 1445 patients in clinical trials to examine the effects of concomitant medications on clearance or volume of distribution of dofetilide. Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs. Differences in clearance between patients on these medications (at any occasion in the study) and those off medications varied between -16% and +3%. The mean clearances of dofetilide were 16% and 15% lower in patients on thiazide diuretics and inhibitors of tubular organic cation transport, respectively.
Participants will receive rivaroxaban 15mg tablet to be taken orally once daily for 7 days. Follow up will be within 30 days where participants will undergo a Doppler ultrasound to assess for radial artery patency/occlusion.
268,655. Agopian, L. A. Sept. 24, 1926. Drawings to Specification. Extracts, making.-Concentrated preparations of vitamin A are obtained by crushing or macerating fresh vegetables or fruit, immediately treating both the juice and the pulped residue with a reagent such as acetate of lead or of copper or both, separating, washing, drying, and crushing the precipitate or cake, and then subjecting it to a cold extraction process, as with petroleum ether, and finally concentrating in vacuo. The product may be purified by treatment with methyl alcohol or by saponification with alcoholic potash. The preparation may be mixed with an oil such as ground-nut oil or olive oil, or with an edible fat such as margarine. Specification 168,903 is referred to.
For treatment of abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology:

One 25 mg injection, intravenously or intramuscularly. Intravenous use is preferred since more rapid response can be expected from this mode of administration. Repeat in 6 to 12 hours if necessary. The use of Premarin Intravenous for injection does not preclude the advisability of other appropriate measures.

One should adhere to the usual precautionary measures governing intravenous administration. Injection should be made SLOWLY to obviate the occurrence of flushes.

Infusion of Premarin Intravenous for injection with other agents is not generally recommended. In emergencies, however, when an infusion has already been started it may be expedient to make the injection into the tubing just distal to the infusion needle. If so used, compatibility of solutions must be considered.